Epidemiology and treatment of left ventricular hypertrophy in the elderly.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Coronary Artery Disease

• Publication date

  1999-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00019501-199912000-00013PMID 10599543
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study.

  2020cited by this paper
• Effect of Antihypertensive Treatment with Doxazosin on Insulin Sensitivity and Fibrinolytic Parameters

  1998cited by this paper
• Prognostic significance of serial changes in left ventricular mass in essential hypertension.

  1998cited by this paper
• The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.

  1997cited by this paper
• The calcium antagonist controversy: the emerging importance of drug formulation as a determinant of risk.

  1997cited by this paper
• Use of beta-blocking agents in secondary prevention after myocardial infarction: a case for evidence-based medicine? GISSI experience, 1984-1993. The Gruppo Italiano di Studio sulla Sopravvivenza nell'Infarto Miocardico (GISSI) Investigators.

  1997cited by this paper
• Calcium channel blockers: an evidence-based review.

  1997cited by this paper
• Calcium channel blockers for hypertension: dissecting the evidence for adverse effects.

  1997cited by this paper
• Physical performance is preserved after regression of left ventricular hypertrophy.

  1997cited by this paper
• Cardiovascular risk factors in the elderly

  1997cited by this paper
• Beta-Blocking Drugs and Coronary Heart Disease

  1997cited by this paper
• Comparison of therapeutic studies on regression of left ventricular hypertrophy.

  1997cited by this paper
• Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

  1997cited by this paper
• Prevalence of left ventricular hypertrophy in a hypertensive population.

  1996cited by this paper
• Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Relationship to changes in skeletal muscle blood flow.

  1996cited by this paper
• 1,4-Dihydropyridines versus beta-blockers for hypertension: Are either safe for the heart?

  1996cited by this paper
• Treatment and post-treatment effects of alpha- versus beta-receptor blockers on left ventricular structure and function in essential hypertension.

  1996cited by this paper
• Cardioprotection and antihypertensive therapy: the key importance of addressing the associated coronary risk factors (the Framingham experience).

  1996cited by this paper
• Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial).

  1996cited by this paper
• Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies.

  1996cited by this paper
• Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials

  1996cited by this paper
• Prevention and reduction of left ventricular hypertrophy in the elderly.

  1996cited by this paper
• The beta 1 hyperselectivity in beta-blocker treatment.

  1995cited by this paper
• Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS).

  1995cited by this paper
• Treatment of hypertension in the elderly

  1995cited by this paper
• Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment

  1995cited by this paper
• Clinical misconceptions dispelled by epidemiological research.

  1995cited by this paper
• Should dihydropyridines be used as first-line drugs in the treatment of hypertension? The con side.

  1995cited by this paper
• Effects of Angiotensin-Converting Enzyme Inhibitors, Ca2+ Channel Antagonists, and α-Adrenergic Blockers on Glucose and Lipid Metabolism in NIDDM Patients With Hypertension

  1995cited by this paper
• Established risk factors and coronary artery disease: the Framingham Study.

  1994cited by this paper
• Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy.

  1994cited by this paper
• Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study.

  1994cited by this paper
• Individualization of therapy for hypertension in the 1990's: the role of calcium antagonists.

  1994cited by this paper
• Antihypertensive effects of calcium antagonists. Clinical facts and modulating factors.

  1994cited by this paper
• Left ventricular hypertrophy: epidemiological prognosis and associated critical factors.

  1993cited by this paper
• Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party.

  1992cited by this paper
• Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin.

  1992cited by this paper
• Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Multicenter trial.

  1992cited by this paper
• Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies.

  1992cited by this paper
• Comparison of the effects of isradipine and lisinopril on left ventricular structure and function in essential hypertension.

  1992cited by this paper
• Left ventricular hypertrophy as a risk factor in arterial hypertension.

  1992cited by this paper
• How far should blood pressure be lowered?

  1992cited by this paper
• The Prognostic Role of Left Ventricular Hypertrophy in Patients with or without Coronary Artery Disease

  1992cited by this paper
• Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension.

  1991cited by this paper
• Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

  1991cited by this paper
• Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension.

  1991cited by this paper
• Reversal of left ventricular hypertrophy by terazosin in hypertensive patients.

  1990cited by this paper
• Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed.

  1990cited by this paper
• Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study.

  1989cited by this paper
• Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study.

  1987cited by this paper
• Use of nuclear magnetic resonance imaging to show regression of hypertrophy with ramipril treatment.

  1987cited by this paper
• Standardization of M-mode echocardiographic left ventricular anatomic measurements.

  1984cited by this paper
• Development and regression of left ventricular hypertrophy.

  1984cited by this paper
• Prevalence and natural history of electrocardiographic left ventricular hypertrophy.

  1983cited by this paper
• Echocardiographic Assessment of Cardiac Anatomy and Function in Hypertensive Subjects

  1979cited by this paper

• Congestive heart failure: a review and case report from a chiropractic teaching clinic.

  2005cites this paper
• Marinobufagenin may mediate the impact of salty diets on left ventricular hypertrophy by disrupting the protective function of coronary microvascular endothelium.

  2005cites this paper
• Marinobufagenin may mediate the impact of salty diets on left ventricular hypertrophy by disrupting the protective function of coronary microvascular endothelium.

  2004cites this paper
• Epidemiology and Problems with Diagnosis of Heart Failure

  2001cites this paper